Status:
COMPLETED
Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma
Lead Sponsor:
University Health Network, Toronto
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
Despite recent advances in cancer treatment, little impact has been made on curing as opposed to controlling cancers over the last several decades. Part of the problem is that investigators have an in...
Detailed Description
Study population: BRAF mutant melanoma patients Pre-mortem bloods will be taken from the patient on three occasions at one to thirty days apart from each other, with the first blood draw taking place...
Eligibility Criteria
Inclusion
- UHN adult patient with BRAF mutant melanoma
Exclusion
- Non BRAF mutant melanoma patient Pediatric patient Non-UHN patient
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 22 2018
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT02251314
Start Date
September 1 2014
End Date
April 22 2018
Last Update
May 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9